
Niall Kirk, Friend and Founder of Optimum Strategic Communications
It is with great sadness that we have to inform you that our…

Optimum Strategic Communications 12th Annual Healthcare Investor Conference
- Future of healthcare conference in partnership with Dechert…

Optimum recognised for its work in the M&A PR advisor league tables
The Optimum team is very proud to be recognised for our work…

Optimum European Healthcare Investor Survey
European investors continue actively investing in healthcare. The survey held in May 2020 includes responses from 24 of the most influential European VCs, investing approximately EUR 15.5 billion in aggregate in the Healthcare sector.

Optimum European Healthcare Investor Survey
Optimum Strategic Communications (Optimum), conducted a survey of European Venture Capital (VC) investors and the impact of COVID-19 on the Healthcare Sector.

Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:…

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer
Key hires enhance management for next development phase
09 January…

Ori Biotech announces a $9.4M seed round to advance innovation in Cell and Gene Therapy manufacturing
Syndicate includes leading UK investors Amadeus Capital Partners,…

Optimum Strategic Communications Expands Team with Appointment of Shabnam Bashir
08 January 2020, London, UK: Optimum Strategic Communications…

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:…

Edinburgh Molecular Imaging Closes Financing
To accelerate development of molecular targeted systemic radiotherapy…

Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company
Forendo Pharma, a clinical stage drug development company focusing…

STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition
09 December 2019, Cambridge, UK: STORM Therapeutics, the biotechnology…

ImaginAb Initiates Phase II Clinical Trial at Penn Medicine
LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- ImaginAb Inc., a clinical-stage…

Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home
Enzyre, which is developing breakthrough ambulant diagnostic…

IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress
IXICO plc (AIM: IXI), the AI data analytics company delivering…

Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning
PARIS and NEW YORK, Dec. 2, 2019 /PRNewswire/ -- Owkin, which…

European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal
LANGENFELD, Germany, Nov. 28, 2019 /PRNewswire/…

Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs
Date: November 26, 2019
Location: Copenhagen
Martin…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York